420Patients.com is accepting qualified medical marijuana patients and caregivers to join our network. We value every registered member and we hope to serve you in Arizona. This article brought to you by 420 community friends mmjbusinessdaily.com
Brazil’s health care regulator, Anvisa, handed out the nation’s first license for the sale of a cannabis-based drug – one designed for the treatment of multiple sclerosis.
According to Reuters, U.K.-based GW Pharmaceuticals PLC developed the marijuana-based oral spray, which is known internationally as Sativex. It will be marketed in Brazil as Mevatyl.
Anvisa announced Monday it had issued a license to São Paulo-based Beaufour Ipsen Farmacêutica to sell and distribute the drug.
Sativex is already sold in 28 other countries, according to Anvisa.
For several years, Brazilian patients have waged a legal battle to get around prohibitions